| Metric | Value | Detail |
|---|---|---|
| Revenue | $65.0B | +1.3% YoY |
| Net income | $18.3B | 28.1% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | n/a | Operating income / revenue |
| Return on equity | 35% | Net income / equity |
| Return on assets | 13% | Net income / assets |
| Revenue growth (YoY) | +1.3% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +3.1% | Compound annual |
| Diluted EPS | $7.30 | FY2025 |
| Debt-to-equity | 0.89 | Long-term debt / equity |
| Current ratio | 1.54 | Current assets / liabilities |
| Cash & equivalents | $14.7B | Balance sheet |
| Total assets | $136.9B | FY2025 year-end |
| Shareholders’ equity | $52.7B | FY2025 year-end |
| Share price | $123.54 | Delayed · 2026-07-10 |
| Market cap | $305.1B | Price × shares outstanding |
| P/E ratio | 16.7 | Market cap / net income |
| P/S ratio | 4.7 | Market cap / revenue |
| Dividend yield | 2.66% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
Merck & Co., Inc. (MRK) stock fundamentals
Merck & Co., Inc. (MRK) reported $65.0B in revenue and $18.3B in net income in fiscal 2025, a 28.1% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $305.1B at a delayed share price. It scores 60/100 on WealthyBud's Investor Score, ranking #28 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$65.0B
▲ +1.3% YoY
Net income
$18.3B
28.1% net margin
Market cap
$305.1B
Price $123.54 · delayed
P/E ratio
16.7
Price / earnings
Return on equity
35%
Net income / equity
Investor Score
60/100
#28 of 100 covered
Merck & Co., Inc. fundamentals at a glance
The table summarizes Merck & Co., Inc.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is Merck & Co., Inc.?
Merck & Co., Inc. runs a 28.1% net margin and n/a gross margin in fiscal 2025, turning $65.0B of revenue into $18.3B of profit. Return on equity is 35% and return on assets 13%.
Is Merck & Co., Inc. growing?
Merck & Co., Inc.'s revenue changed +1.3% in fiscal 2025 and compounded at +3.1% a year over three years, reaching $65.0B. Diluted earnings per share were $7.30 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $48.7B | n/a |
| 2022 | $59.3B | +21.7% |
| 2023 | $60.1B | +1.4% |
| 2024 | $64.2B | +6.7% |
| 2025 | $65.0B | +1.3% |
How is Merck & Co., Inc. valued?
Merck & Co., Inc. carries a market capitalization of $305.1B at a delayed share price of $123.54, trading at a 16.7 price-to-earnings ratio and 4.7 price-to-sales with a 2.66% dividend yield. Its Value subscore is 67/100 across the covered universe.
How financially healthy is Merck & Co., Inc.?
Merck & Co., Inc. ended fiscal 2025 with $14.7B in cash, a debt-to-equity ratio of 0.89 and a current ratio of 1.54. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is Merck & Co., Inc.'s Investor Score?
Merck & Co., Inc. scores 60/100 on WealthyBud's Investor Score, #28 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
60/100
#28 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
Merck & Co., Inc. (MRK) stock FAQ
How much revenue does Merck & Co., Inc. make?
Merck & Co., Inc. (MRK) reported $65.0B in revenue in fiscal 2025, +1.3% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +3.1% a year.
Is Merck & Co., Inc. profitable?
Yes. Merck & Co., Inc. earned $18.3B in net income in fiscal 2025, a 28.1% net margin. Its return on equity was 35% and return on assets 13%, based on figures from its latest 10-K.
How fast is Merck & Co., Inc. growing?
Merck & Co., Inc.'s revenue changed +1.3% year over year in fiscal 2025 and compounded at +3.1% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 36/100 versus the covered universe.
What is Merck & Co., Inc.'s market cap and P/E ratio?
Merck & Co., Inc. has a market capitalization of $305.1B at a delayed share price of $123.54, trading at a price-to-earnings ratio of 16.7 and price-to-sales of 4.7. Its dividend yield is 2.66%. Prices are delayed and illustrative.
What is Merck & Co., Inc.'s WealthyBud Investor Score?
Merck & Co., Inc. scores 60/100, ranking #28 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (36), profitability (74), returns on capital (73), balance-sheet strength (54) and value (67). It is a research opinion, not investment advice.
Where does this Merck & Co., Inc. financial data come from?
Fundamentals come from Merck & Co., Inc.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Merck & Co., Inc.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.